TrialScientific reports2024

Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial.

Mohammad Ali Sahraian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.